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GMO Regulatory Aspects of Novel 
Investigational Vaccine Candidates
Amaya Leunda and Katia Pauwels
Abstract
Recent scientific and technical developments create novel opportunities for 
vaccine development. Regulatory compliance has to be ensured from preclinical 
research to market authorization, whereby different legal frameworks that go 
beyond quality, efficacy or patient safety aspects need to be taken into account. 
As academia and start-ups are often focused on gathering scientific evidence, 
the regulatory maze is often regarded by applicants as challenging in the overall 
pathway to clinical translation. This is particularly true for applications concern-
ing vaccine candidates containing or consisting of genetically modified organisms 
(GMOs). Active communication between applicants and competent authorities or 
advisory bodies early in the development stages facilitates a correct implementation 
of the regulatory frameworks and is of utmost importance to identify challenges 
or hurdles in order to avoid unnecessary delay in scientific review. Based on the 
state-of-play in Belgium, this chapter discusses examples of regulatory journeys of 
applications with genetically modified viral vectors and novel vaccine candidates 
that have been reviewed by GMO national competent authorities in Belgium and in 
Europe. They highlight the need of having a comprehensive view of global perspec-
tives early in the development to facilitate the translation of research to clinical 
development or even market authorization.
Keywords: novel vaccine candidates, GMO, European directives, regulatory 
challenges, environmental risk assessment
1. Introduction
Recent progress in disease comprehension combined with new technology 
performances creates novel opportunities for vaccine development in various health 
sectors. The last decade has seen a significant increase in the development of pro-
phylactic medicines aiming at preventing infectious diseases or immunotherapeutic 
products to fight non-infectious diseases such as cancers. Both biopharmaceuticals 
are regarded as vaccines because they elicit an immune response, either against a 
pathogenic microorganism or against the host’s own tumour cells. Among these 
investigational medicinal products (IMP) for human use currently studied in clini-
cal trials (CT), various candidate vaccines contain or consist of genetically modified 
organisms (GMOs). For the purpose of this chapter, this subset of IMPs will be 
further referred to as GMO vaccine candidates.
As for any medicinal product, the clinical translation of research data is subject 
to a stringent regulatory framework, with procedures to ensure the quality, safety 
and efficacy of the product in humans. To conduct a new CT in one country of the 
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European Union (EU), a clinical trial authorization must be obtained from the 
national competent authority, and the CT must be approved by an ethics commit-
tee. In the case of a CT involving a GMO vaccine candidate or any IMP containing 
or consisting of a GMO, an authorization should also be compliant with the provi-
sions of the legislation regarding the use of GMOs.
With the increasing number of authorization requests for CT with a GMO vac-
cine candidate and the new techniques that emerge for the construction of GMOs, 
the applicants, the national competent authorities and the different advisory bodies 
are facing some hurdles that may hamper the initiatives undertaken in the clinical 
translation of vaccine development in Europe. A first challenge originates from 
the several legislations with which the conduct of a CT with a GMO should comply 
in the country where the CT is planned. Different legislations are often under the 
control of different institutional bodies that may not necessarily interrelate and that 
may not be easily identified by applicants (see the example of Belgium in Figure 1). 
To a lesser extent, the obligation to follow distinct procedural regulations and the 
subsequent administrative burden may be a deterrent for them. Similarly, the appli-
cant who plans to undertake a CT with a GMO vaccine candidate in multiple mem-
ber states of the EU can be confronted with an equal number of country-specific 
procedures. Indeed, contrary to the standard CTA and ethics committee approval 
procedures for a CT, national GMO regulatory frameworks are not fully harmo-
nized across the EU, and procedures for application may differ from one country to 
another. Finally, along with the emergence of new techniques intended for genetic 
modification, both applicants and authorities or advisory bodies are confronted with 
an increasing number of questions with respect to the interpretation of the defini-
tion of a GMO as laid down in the European GMO legislation.
These challenges have the merit of prompting the debate between the differ-
ent actors and to initiate exchanges at national and European level with the aim 
to foster a continued dynamic in innovative research, while ensuring the safety of 
human health and environment. By means of several examples, this book chapter 
illustrates several aspects of the implementation of the GMO legislation that are of 
Figure 1. 
Overview of Belgian regulatory framework for clinical trials involving an investigational medicinal product 
containing or consisting of GMOs. STA, scientific and technical advice; FAMHP, Federal Agency of Medicines 
and Health Products; CU, contained use; DR, deliberate release; EC, Ethics Committee; CTA, clinical trial 
application. (1) The FAMHP offers to the applicant the possibility to request a STA prior to other mandatory 
procedures. The STA provides clarity on the GMO status of the IMP involved and the mandatory procedures 
to follow. (2) The CU procedure is applied to activities with the GMO vaccine candidate taking place in 
a ‘contained’ facility. The regional authorities and Sciensano as the advisory body are involved in the CU 
procedure. The CU procedure and approval are independent of those also associated to a clinical trial. (3) 
The DR procedure is required when there is a probability of possible release of the GMO into the environment 
during the clinical trial. An application is submitted to the competent authority, the FAMHP. The application 
is evaluated by the advisory body (Biosafety Advisory Council) which transmits its advice to the FAMHP. An 
application under DR framework does not exempt an application under the CU procedure. (4 and 5) Following 
the national law of 7 May 2004 related to experiments on human, a clinical trial cannot start without a 
positive advice of the (leading) ethics committee and competent authority.
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relevance to CTs with a GMO vaccine candidate. The current state of discussions, 
an analysis of some of the hurdles that may hamper a smooth clinical translation as 
well as different options that are available to applicants are reviewed with respect to 
the Belgian and European regulatory frameworks.
2. Regulatory requirements for GMOs
2.1 The European regulatory framework
The European legislation on GMOs consists of two main Directives covering 
the use of genetically modified microorganisms (GMMs) in a contained facility 
(Directive 2009/41/EC) [1] and the deliberate release of GMOs into the environ-
ment (Directive 2001/18/EC) [2]. These Directives are mainly aimed at protecting 
the general population and the environment from potential risks arising from the 
use of GMMs and GMOs.
According to these Directives GMOs and GMMs are defined as organisms, with 
the exception of human beings, in which the genetic material has been altered in 
a way that does not occur naturally by mating and/or natural recombination. The 
definition of a GMO is both technology and process oriented: an organism will fall 
under the scope of the GMO regulations if it has been developed with the use of 
certain techniques. Therefore the EU Directives include annexes supplying informa-
tion regarding the techniques that result in genetic modification, those that are not 
considered to result in genetic modification or those that result in genetic modifica-
tion but yield organisms that are excluded from the scope of the directives (Table 1).
The GMO aspects of clinical trials with medicinal products containing or 
consisting of GMOs, including GMO vaccine candidates, are governed by national 
procedures implementing the GMO Directives. However, not all member states 
have the same approach in implementing provisions relating to deliberate release 
(DR) into the environment (Directive 2001/18/EC) and/or contained use (CU) 
(Directive 2009/41/EC) in the specific case of clinical trials. A first report on the 
approaches adopted by several member states in this matter has been commissioned 
by the European Commission (EC) and dates back to 2007 [3]. In 2018, recogniz-
ing the developments in novel medicinal products and the need of applicants of 
investigational products to have an up-to-date overview of regulatory requirements, 
a repository of national requirements was created [4]. The approaches adopted 
by Bulgaria, Germany, Hungary, Ireland, Slovakia, Slovenia, Spain, Sweden and 
the Netherlands on the one hand, and those prevailing in Denmark on the other, 
illustrate two extremes. In the first mentioned member states, only the ‘‘Deliberate 
Release’ framework is used to assess and manage the risks for human health and the 
environment, while in Denmark the biological confinement of medicinal products 
containing or consisting of GMOs and their use in controlled hospital environments 
trigger the application of the ‘Contained Use’ regulatory framework only.
One of the important differences between Directive 2009/41/EC and Directive 
2001/18/EC is that the latter requests the applicant to submit an environmental risk 
assessment (ERA). An ERA implies an assessment of the environmental impact of 
the GMO with regard to the potential risks for human health and the environment. 
Purely medical aspects concerning the efficacy of the IMP and its safety for the 
treated patient, as well as aspects related to social, economic or ethical consider-
ations, are outside the scope of the ERA report. The ERA methodology for GMOs 
developed over the past decades is largely harmonized in many legislative systems 
and comprises the following steps: (1) hazard identification, (2) hazard charac-
terization, (3) assessment of likelihood, (4) risk estimation and (5) evaluation of 
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Directive 2009/41/EC Directive 2001/18/EC
Article 2
(a) ‘micro-organism’ means any microbiological entity, 
cellular or non-cellular, capable of replication or of 
transferring genetic material, including viruses, viroids, 
animal and plant cells in culture;
(b) ‘genetically modified micro-organism’ (GMM) shall 
mean a micro-organism in which the genetic material has 
been altered in a way that does not occur naturally by mating 
and/or natural recombination.
Within the terms of this definition:
(i) genetic modification occurs at least through the use of the 
techniques listed in Annex I, Part A;
(ii) the techniques listed in Annex I, Part B, are not 
considered to result in genetic modification;
Article 3
[...] this Directive shall not apply:
- where genetic modification is obtained through the use of 
the techniques/methods listed in Annex II, Part A
Article 2
(1) ‘organism’ means any biological entity 
capable of replication or of transferring 
genetic material;
(2) ‘genetically modified organism (GMO)’ 
means an organism, with the exception of 
human beings, in which the genetic material 
has been altered in a way that does not 
occur naturally by mating and/or natural 
recombination;
Within the terms of this definition:
(a) genetic modification occurs at least 
through the use of the techniques listed in 
Annex I A, Part 1;
(b) the techniques listed in Annex I A, Part 
2, are not considered to result in genetic 
modification.
Article 3.1
This Directive shall not apply to organisms 
obtained through the techniques of genetic 
modification listed in Annex I B.
Annex I
Part A
Techniques of genetic modification referred to in Article 
2(b)(i) are, inter alia:
(1) Recombinant nucleic acid techniques involving the 
formation of new combinations of genetic material by the 
insertion of nucleic acid molecules produced by whatever 
means outside an organism, into any virus, bacterial 
plasmid or other vector system and their incorporation into 
a host organism in which they do not naturally occur but in 
which they are capable of continued propagation.
(2) Techniques involving the direct introduction into a 
micro-organism of heritable material prepared outside 
the micro-organism including micro-injection, macro-
injection and micro-encapsulation.
(3) Cell fusion or hybridisation techniques where live cells 
with new combinations of heritable genetic material are 
formed through the fusion of two or more cells by means of 
methods that do not occur naturally.
Annex I A
Techniques referred to in Article 2(2)
Part 1
Techniques of genetic modification referred to 
in Article 2(2)(a) are inter alia:
(1) Recombinant nucleic acid techniques 
involving the formation of new combinations 
of genetic material by the insertion of nucleic 
acid molecules produced by whatever means 
outside an organism, into any virus, bacterial 
plasmid or other vector system and their 
incorporation into a host organism in which 
they do not naturally occur but in which they 
are capable of continued propagation;
(2) Techniques involving the direct 
introduction into an organism of heritable 
material prepared outside the organism 
including micro-injection, macro-injection 
and micro-encapsulation;
(3) Cell fusion (including protoplast fusion) 
or hybridisation techniques where live cells 
with new combinations of heritable genetic 
material are formed through the fusion of two 
or more cells by means of methods that do not 
occur naturally.
Annex I
Part B
Techniques referred to in Article 2(b)(ii) which are not 
considered to result in genetic modification, on condition 
that they do not involve the use of recombinant-nucleic acid 
molecules or GMMs made by techniques/ methods other than 
techniques/methods excluded by Annex II, Part A:
(1) in vitro fertilisation;
(2) natural processes such as: conjugation, transduction, 
transformation;
(3) polyploidy induction.
Annex I A
Techniques referred to in Article 2(2)
Part 2
Techniques referred to in Article 2(2)(b) 
which are not considered to result in genetic 
modification, on condition that they do not 
involve the use of recombinant nucleic acid 
molecules or genetically modified organisms 
made by techniques/methods other than those 
excluded by Annex IB:
(1) in vitro fertilisation,
(2) natural processes such as: conjugation, 
transduction, transformation,
(3) polyploidy induction.
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risk management options followed by (6) a conclusion on the acceptability (or not) 
of the overall impact of the use of the GMO on human health and the environ-
ment, taking into account the management strategies applied. Another feature of 
Directive 2001/18/EC is the mandatory public consultation.
In the context of a marketing authorization application (MAA), it is important 
to note that Regulation (EC) No 726/2004 [5] laying down procedures for authori-
zation and supervision of medicinal products requests an ERA similar to the ERA 
applied under Directive 2001/18/EC for medicinal products containing or consist-
ing of GMOs. In practice, the scientific evaluation of the GMO, like any other MAA, 
is performed through a centralized authorization procedure across the EU. During 
this process, the European Medicines Agency holds consultations with the compe-
tent authorities (CA) of each member states established under Directive 2001/18/
EC with respect to the evaluation of the environmental risk aspects. Therefore, even 
though a contained use-only procedure may have been accepted for a CT involving 
a GMO, an ERA will need to be submitted according to the provisions of Regulation 
(EC) 726/2004 should the IMP reach MAA.
2.2 State of the art in Belgium
In Europe, Belgium is one of the most active countries in terms of CTs undertaken 
with GMO vaccine candidates [6]. This is also observed by the total number of 
requests submitted to the Belgian authorities for new CTs involving an IMP contain-
ing or consisting of a GMO from 2009 to 2018 (Figure 2). Until 2018, the number of 
requests registered annually remained relatively stable, after which a marked increase 
was observed. These applications involve CT with IMP containing or consisting of a 
Directive 2009/41/EC Directive 2001/18/EC
Annex II
Part A
Techniques or methods of genetic modification yielding 
micro-organisms to be excluded from the Directive on the 
condition that they do not involve the use of recombinant-
nucleic acid molecules or GMMs other than those produced 
by one or more of the techniques/methods listed below:
(1) Mutagenesis.
(2) Cell fusion (including protoplast fusion) of prokaryotic 
species that exchange genetic material by known 
physiological processes.
(3) Cell fusion (including protoplast fusion) of cells of any 
eukaryotic species, including production of hybridomas and 
plant cell fusions.
(4) Self-cloning consisting in the removal of nucleic acid 
sequences from a cell of an organism which may or may not 
be followed by reinsertion of all or part of that nucleic acid 
(or a synthetic equivalent) with or without prior enzymic or 
mechanical steps, into cells of the same species or into cells of 
phylogenetically closely related species which can exchange 
genetic material by natural physiological processes where 
the resulting micro-organism is unlikely to cause disease to 
humans, animals or plants.
Self-cloning may include the use of recombinant vectors 
with an extended history of safe use in the particular 
micro-organisms.
Annex I B
Techniques referred to in Article 3
Techniques/methods of genetic modification 
yielding organisms to be excluded from the 
Directive, on the condition that they do not 
involve the use of recombinant nucleic acid 
molecules or genetically modified organisms 
other than those produced by one or more of 
the techniques/methods listed below are:
(1) mutagenesis,
(2) cell fusion (including protoplast fusion) 
of plant cells of organisms which can 
exchange genetic material through traditional 
breeding methods.
Modified from [31].
Table 1. 
The definition of a GMO according to the EU directives [1, 2].
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GMO developed against infectious diseases or cancer, as well as CT with GMOs aiming 
to treat cardiovascular, autoimmune or hereditary diseases, gastrointestinal disorder 
or inflammation. Among all these IMPs, around 70% consist of GMO vaccine candi-
dates for prophylactic or therapeutic purposes (data not showed).
GMO vaccine candidates are mainly composed of viral vectors containing one or 
more specific genetic sequences whose expression in the human body will enhance 
the immune response against an infectious agent or tumour cells (Figure 3). 
Recently, an increasing number of clinical studies have been realized using autolo-
gous or allogenic immune cells that have been genetically modified ex vivo in order 
to express specific receptors able to recognize tumour cells when infused back into 
the patient body [7]. A minor part of the GMO vaccine candidates consists of the 
targeted infectious microorganism which is genetically modified in vitro to become 
attenuated yet still capable to trigger an immune response.
In Belgium a clinical trial with an IMP containing or consisting of a GMO can 
fall into the framework of the CU only or the CU and DR legislations. The GMO 
procedural pathway is chosen and applied on a case-by-case basis in order to guar-
antee proportionate and scientifically robust evaluations. To aid in the determina-
tion of the legal procedure(s), the applicant is invited to evaluate if at any stage of 
the CT, the general population and the environment can be exposed to the IMP.
In case physical barriers, or a combination of physical barriers together with 
chemical and/or biological barriers, are used to limit the contact with the general 
population and the environment, the CT and related activities have to comply with 
the Belgian legislation on CU of GMOs. Generally, activities such as the prepara-
tion, administration or storage of the IMP should follow the CU procedure only.
In general, a CU procedure suffices when there is no possible release of the 
GMO in the environment (e.g. the GMO is administered in clinical centres only, 
and there is no spreading of the GMO when subjects leave the centre) or if proper 
management procedures and/or working practices are implemented to prevent such 
a release. On the contrary, when there is a probability of release into the environ-
ment (e.g. the subject leaves the clinical centre, and close contacts of the subject 
may become exposed to the GMO) which cannot be avoided by proper management 
procedures or working practices, a notification according to the DR procedure 
Figure 2. 
Number of new clinical trials involving an investigational medicinal product containing or consisting of GMOs 
since 2009 to 2018 in Belgium. A new clinical trial with a GMO can take place in different clinical centres 
at the same time. The investigational medicinal product can be directed against infectious, cardiovascular, 
autoimmune or hereditary diseases but also gastrointestinal disorders, inflammation or cancer.
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will additionally be required, and an ERA should be performed. Considerations 
that are taken into account to determine if a DR notification is needed are the 
probability of shedding of the GMO, hazards associated to the shedding should it 
occur, probability of spreading, or whether the GMO is also taken (administered) at 
home. Procedures for clinical trials within the DR framework are perceived as more 
cumbersome than those under CU, both for the applicants and for the governmental 
institutions that are reviewing the applications.
3.  New technologies for vaccine development facing regulatory 
frameworks
For many human infectious diseases no satisfactory vaccine is currently avail-
able. Hence, public health needs are continuous incentives for further research 
and development. Scientific advances not only contributed to the development of 
novel vaccines that trigger the immune system for prophylactic purposes against 
infectious diseases but also offered opportunities in gene transfer for (cancer) 
immunotherapy and the treatment of tumours. Numerous examples have reached 
clinical development and in some cases even commercialization, even though the 
interpretation and/or implementation of the regulatory maze is often regarded as 
challenging by applicants. This section discusses recent developments illustrating 
the unique features and challenges for GMO vaccines with respect to the current 
GMO regulation.
3.1 Dengvaxia
Dengvaxia is a GMO vaccine that recently obtained marketing authorization 
in the EU. This live attenuated vaccine is indicated for the prevention of dengue 
disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals living in 
endemic areas. The vaccine was developed using the attenuated yellow fever vaccine 
strain as a vector, which has been genetically modified to express the prM and E 
genes from the four different dengue virus serotypes. The administered vaccine 
thus contains four different virus constructs, each of which contains the prM and 
E genes from a different dengue virus serotype. Dengue is by far the most common 
Figure 3. 
Types of GMOs used as investigational medicinal products in clinical trials carried out in Belgian clinical 
centres and corresponding percentage of the total requests from 2009 to 2018. Globally, three main types 
of GMOs are used: autologous or allogeneic human cells that have been genetically modified ex vivo and 
reintroduced in a human body (blue), viral vectors genetically modified to carry the gene sequence of interest 
(orange) and attenuated derivatives of microorganisms that can operate as vaccines (grey).
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mosquito-borne viral disease. It is transmitted by Aedes mosquitoes and infects 
people worldwide (mainly in tropical areas). Tens of millions of cases occur each 
year resulting in approximately 20,000–25,000 deaths, mainly in children [8]. 
Because four serologically distinct dengue viruses coexist in dengue-endemic areas, 
several dengue infections are possible during the patient’s lifetime.
The ERA, conducted according to the principles laid down in Directive 
2001/18/EC, included among others a consideration of the severity and likelihood 
of recombination or mutational events that would change the attenuated pheno-
type of the viral vector to one of virulence. The capacity of the GMO to replicate, 
disseminate and be transmitted by the Aedes mosquitoes was also evaluated. In 
addition, both shedding data of subjects receiving the recombinant viruses and the 
probability of mosquitoes or ticks transmitting the recombinant virus after oral 
feeding were considered in order to assess the likelihood of dissemination in the 
human population.
Another aspect that was considered in the context of Directive 2001/18/EC is 
the detection, traceability and labelling of GMOs. These legal aspects have been 
further regulated into sectoral legislation for genetically modified food and feed 
as part of their EU authorization procedure (Regulation EC 1829/2003) [9], and 
several recommendations have been issued on how analysis methods should be 
evaluated and validated by the EU Reference Laboratory for Genetically Modified 
Food and Feed (EURL GMFF). Though Directive 2001/18/EC also covers IMP 
containing or consisting of GMOs, no sectorial legislation has been developed for 
IMP. Instead, as Regulation 726/2004, Art 6 (2), refers to Annex IV of Directive 
2001/18/EC, traceability must be ensured at all stages of the placing on the 
market of GMOs (Table 2). However, compared to traceability requirements of 
genetically modified food and feed, it should be noted that much less experi-
ence has been gained so far with the validation of methods for the traceability 
of medicinal GMOs and no such laboratory network has been established to 
enforce traceability requirements at the European level. During the evaluation 
of the marketing authorization application of Dengvaxia, it was noticed that 
traceability methods proposed by the applicant referred to control and monitor-
ing approaches for potentially contaminated effluents at manufacturing sites. 
However such methods are usually not adapted nor validated for detecting 
transfer of the donated genetic material to other organisms because the matrix 
in which the GMOs are supposed to be detected usually differ from those such as 
effluents of manufacturing sites.
3.2 Plasmid-based live attenuated virus
One of the new avenues to develop novel types of vaccines is the plasmid-based 
live attenuated virus technology [10]. Upon identification of the protective antigen, 
this next-generation vaccine platform technology potentially provides for a rapid, 
versatile and cost-effective vaccine response platform to infectious diseases. The 
technology circumvents the manufacturing of free live attenuated viral particles 
as such, which is subject to high-quality control requirements. Instead the genome 
of an attenuated virus is inserted into human cells by means of a plasmid vector. 
Human cells that are harbouring the plasmid vector enable the in vivo replication 
of live-attenuated virus (LAV), thereby potentially eliciting immune response and 
hence immunogenicity. Proof of concept has been delivered for a yellow fever virus 
strain, and ongoing research will now explore the use of recombinant LAVs as novel 
vaccines.
The approach of plasmid-based LAV vaccines exemplifies how the pace of 
innovation and converging technologies may blur current distinctions between a 
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GMO and a non-GMO, and hence the legal status with regard the legislation on 
GMOs. Such rapidly evolving fields may also challenge a harmonized understand-
ing of legal definitions across different countries. With respect to GMO regulation, 
it is not yet clear whether the status of plasmid-based live attenuated viruses will be 
based on a common interpretation among GMO national competent authorities.
A first element that will contribute to the interpretation can be sought in the 
GMO status of vaccines that are based on plasmid DNA derived from bacterial cells 
for use in humans or in animals, the so-called DNA vaccines [11]. Most of the EU 
member states do not regulate DNA vaccines as a GMO. The reasoning behind this 
is that a DNA vaccine is not considered an organism. Likewise, human cells trans-
fected with plasmids should not be classified as GMOs, provided that the plasmid 
is not replicative and is unlikely to integrate into the cell genome. Taking into 
consideration Article 2 of Directives 2001/18 and 2009/41/EC, and corresponding 
annexes (Table 1), nucleic acid material (DNA or RNA) such as plasmids present 
under episomal form in a human cell is not considered as heritable material (of 
the human cell) unless the nucleic acid material is capable of continued propaga-
tion, for example, by integration of the nucleic acid material into the genome of 
the human cell, or when the plasmid contains an origin of eukaryotic replication. 
It should be noted that the probability of integration cannot be totally excluded 
for plasmids not known to contain integrative elements or homologous sequences. 
However, should an integration event occur, the risk for the human population 
or the environment, associated to the use of transfected human cells, would be 
negligible. Indeed, human cells can only propagate inside the human body or 
under controlled in vitro conditions. In terms of potential risks for the human 
population and the environment, it follows that the risk associated to the use of a 
transfected human cell is negligible provided that the plasmid is not replicative or 
not integrative.
Regulation (EC) 726/2004 Directive 2001/18/EC
Article 6 (2)
In the case of a medicinal product for human use 
containing or consisting of genetically modified 
organisms within the meaning of Article 2 of 
Directive 2001/18/EC, the application shall be 
accompanied by:
(a) a copy of the competent authorities’ written 
consent to the deliberate release into the 
environment of the genetically modified organisms 
[…];
(b) the complete technical dossier supplying the 
information required by Annexes III and IV to 
Directive 2001/18/EC;
(c) the environmental risk assessment in 
accordance with the principles set out in Annex II to 
Directive 2001/18/EC; and
(d) the results of any investigations performed for 
the purposes of research or development.
Annex IV
This Annex describes in general terms the additional 
information to be provided in the case of notification 
for placing on the market and information for 
labelling requirements regarding GMOs:
Part A (7)
Information on the genetic modification for the 
purposes of placing on one or several registers 
modifications in organisms, which can be used for 
the detection and identification of particular GMO 
products to facilitate post-marketing control and 
inspection. This information should include where 
appropriate the lodging of samples of the GMO or 
its genetic material, with the competent authority 
and details of nucleotide sequences or other type 
of information which is necessary to identify the 
GMO product and its progeny, for example the 
methodology for detecting and identifying the GMO 
product, including experimental data demonstrating 
the specificity of the methodology. Information that 
cannot be placed, for confidentiality reasons, in the 
publicly accessible part of the register should be 
identified.
Table 2. 
Legal requirements regarding traceability of an IMP containing or consisting of a GMO in the case of 
notification for placing on the market.
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A second element that prompts reflection on the GMO status, which is of particu-
lar relevance for the plasmid-based LAV technology, is associated to plasmids har-
bouring the full sequence of a virus. In that case the plasmid-transfected human cells 
may lead to the generation of replication-competent virus particles in the host human 
cells that eventually can be released into the environment. A plasmid harbouring 
a virus strain that has been genetically modified would be subjected to the GMO 
framework. However, the GMO status of plasmids harbouring the full sequence of a 
naturally occurring virus or attenuated virus has not been determined yet.
3.3 CAR T cells
Therapeutic vaccines for cancer immunotherapy with chimeric antigen receptor 
(CAR) T cells are another medical development exploiting modern biotechnol-
ogy tools. Cancer immunotherapy uses the patient’s own T cells that have been 
engineered to express a receptor targeting an antigen on the surface of tumour cells 
[12–14]. CAR T cell-based immunotherapy has shown remarkable efficacy against 
human malignancies, thereby providing a promising alternative to allogeneic hae-
matopoietic stem cell transplantation which is known to be associated with severe 
side effects. It is anticipated that the number of developments using CAR T cells 
will continue to expand as current research now explores, for example, the potency 
of (CAR) T cells in solid tumours or the use of allogeneic ‘off-the-shelf ’ T cells. The 
rapid pace of developments in part has been facilitated by the implementation of 
gene-editing tools to genetically modify human T cells.
Genome-editing techniques involving the use of site-directed nucleases (SDN), 
like the ribonucleoprotein-mediated gene editing of cells, make it possible to induce 
modifications in a predefined region of the genome without the need to introduce 
foreign (exogenous) DNA [15]. For some applications, the resulting organisms can-
not be distinguished from those generated through classic mutagenesis or spontane-
ous mutations. While addressing how these techniques relate to the European GMO 
legislation and taking into account that organisms developed through classical 
mutagenesis are excluded from the EU regulatory framework for GMOs, a number 
of authorities or advisory bodies of EU members have expressed the opinion that 
applications of SDN, resulting in small point mutation or indels, could be exempted 
from the EU GMO regulation on the condition that the nuclease is not stably 
expressed from a recombinant nucleic acid molecule [16]. Therefore the advent of 
gene-editing techniques was challenging the boundaries of the GM regulation in the 
EU, at least until a legal opinion of the Court of Justice of the EU (ECJ) was issued. 
The ruling declared that organisms produced by mutagenesis techniques, including 
directed mutagenesis and applications of gene editing, should be regulated under 
EU GMO law, unless the mutagenesis technique has conventionally been used in a 
number of applications and has a long safety record [17]. Much opposition has been 
raised against this ruling, in particular with respect to the inclusion of gene-edited 
plants within the remit of GMO legislation [18, 19].
The ruling applies to medicinal GMOs as well and will determine the legal 
status of CAR T cells obtained with gene-editing techniques with respect to GMO 
legislation. Apart from notifications in the context of CTAs, such an IMP would 
also require an ERA when reaching MAA (Regulation (EC) 726/2004). However, 
though human cells may survive in whole blood or synthetic media with a com-
position similar to human blood, these cells can only propagate inside the human 
body or under controlled in vitro conditions. Human cells will not survive in 
non-optimized conditions, and it is highly unlikely that the genetic modification 
of these cells, by means of gene-editing tools, will alter the inherent fitness of 
human cells for survival in the environment upon their release, much less to cause 
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any adverse effects to human health or animal health. It follows that for MAA 
involving the use of gene-edited human (autologous) cells, the risks for human 
health and/or the environment associated to the handling/use of the medical 
product is negligible.
3.4 Novel oral poliovirus type 2 vaccine candidates
The continuous improvements in DNA synthesis technology also hold promise 
in the design of new vaccines. Developers may go further than recombinant DNA 
technology and make a step towards increased rational design, away from existing 
nucleotide sequences. For example, the genetic code of the virus can be redesigned 
so that 100% identity is preserved at the protein level with significant differences at 
the nucleotide level. This codon deoptimization has been described as an approach 
to generate attenuated viruses that can be used as vaccines [20, 21]. The synthesis 
of poliovirus (PV) as early as 2002 is considered as one of the first milestones in 
synthetic genomics [22]. Most recently, a clinical trial has been set-up involving two 
GMOs consisting of novel live attenuated polio vaccine candidates that have been 
developed through advanced DNA synthesis technology and codon deoptimiza-
tion [23]. Though few preliminary questions were related to the GMO status of the 
novel live attenuated polio vaccines, it was merely the context of the global Polio 
Eradication Initiative and the associated efforts to minimize poliovirus facility-
associated risks, as defined in the WHO’s Global Action Plan III (GAP III) [24] that 
added to the complexity of the legal procedure.
Poliovirus has a particular status from a global world health perspective since 
the launch of the global Polio Eradication Initiative in 1988. Immunization with 
trivalent live, attenuated oral poliovirus vaccine (OPV), composed of three strains 
OPV1, 2 and 3, has led to a drastic decline in the number of polio cases worldwide. 
However OPV is genetically unstable and can regain neurovirulence, leading to out-
breaks of circulating vaccine-derived poliovirus (cVDPV). In a context of PV type 2 
eradication worldwide and because the risk associated to the use of OPV2 was out-
weighing the benefits, it was decided to withdraw the type 2 component from OPV 
vaccination campaigns and to introduce the inactivated poliovirus vaccine, which is 
more expensive and relatively more cumbersome to administer. Nevertheless, due to 
its induced superior mucosal immunity, monovalent OPV2 is still used in responses 
to outbreaks of cVDPV2, thereby challenging the feasibility of eradication of PV2 
[25]. It is within this context that a global consortium of investigators, governmen-
tal, non-governmental, academic and global health organizations worked on the 
development of two novel OPV2 vaccine candidates (nOPV2) with better genetic 
stability and reduced risk to regain a neurovirulent phenotype.
The first-in-human (FIH) phase 1 study was conducted in Belgium. Although 
the clinical development of such novel vaccines was considered highly desirable 
from a world health perspective, the launch of a FIH study was considered under 
severe scrutiny in order to avoid any risk of introducing VDPV in a country declared 
polio-free for several years. As shedding of the nOPV2 was anticipated for a mean 
time of 2 weeks, the consortium decided to conduct the FIH phase 1 study with 
voluntary participants under full containment during 28 days, with strengthened 
containment measures. Rather unexpectedly, the study showed that ~50% of the 
subjects still were shedding after having left the full containment period of 28 days. 
Post-discharge biorisk management measures were applied to prevent the release 
of the candidate vaccines in the environment and to avoid contact with immune-
compromised individuals.
The WHO’s Polio Eradication Department encouraged further progress in the 
clinical study of the novel OPV vaccines and the consortium applied for a phase 
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II CT with the nOPV2 vaccine candidates. On the basis of shedding and genetic 
stability data obtained with the FIH study, and the larger size of cohorts to be 
involved during the phase II study, the consortium applied for an authorization for 
deliberate release into the environment of the GMOs. In accordance with the Royal 
Decree transposing Directive 2001/18/EC into Belgian law, an ERA was submitted 
[26], a public consultation was organized, and a notification according to the provi-
sions of Council Decision 2002/813/EC [27], the so-called summary notification 
information format (SNIF), was circulated. This enables an exchange of informa-
tion between the EU member state and the Commission on the basis of relevant 
information.
It has been the first example to our knowledge of EU member states commenting 
on the SNIF. One of the concerns raised by neighbouring countries was the trans-
boundary release of the nOPV2, should the healthy volunteers not stay in Belgium 
during the period of virus shedding. Those concerns are not only related to GMO 
regulatory provisions but also to GAP III requirements, which describe a biorisk 
management system addressing areas associated with the design, operation and 
management for facilities handling poliovirus facilities [28]. It can be concluded 
that the regulatory pathway to the setup of the two first CT involving nOPV2 
revealed an additional complexity involving increased exchanges both at national 
and international levels.
4. Engagement with regulatory agencies or advisory bodies
4.1 Importance of networking
Medicines become more and more the result of different and converging tech-
nologies. For many human infectious diseases, no satisfactory vaccine is currently 
available, and the development of vaccines containing or consisting of GMOs is 
one of the innovative technologies implemented to meet some of the public health 
needs. Regulators involved in medicinal products for humans, as well as in GMOs, 
need to anticipate these developments, not only by enforcing safety regulations 
but also by ensuring the scientific review adheres to the principles of proportional-
ity and case-by-case approach. From the applicants’ side, it is recognized that the 
regulatory pathway for novel technologies is complicated and not always straight-
forward. Early dialogue between applicants, risk assessors and the regulatory 
authorities is therefore paramount in addressing challenges with clinical translation 
of novel GMO vaccines.
The steps that were undertaken towards the approval of early phases of a clini-
cal trial investigating nOPV2 vaccine candidates in a post-OPV2-withdrawal era 
exemplify the importance of liaising among several regulatory agencies and public 
health institutions covering (international) public health objectives at national, 
European and global level. At the time the consortium that worked on the develop-
ment of the nOPV2 vaccine candidates applied for its second clinical trial, it was 
still not clear whether the nOPV2 vaccine candidates were to be considered under 
the scope of GAP III. Because the consortium engaged as early as possible with 
advisory and/or regulatory institutions, the Belgian authorities were prompted to 
ask the WHO’s Containment Advisory Group to clarify the GAP III status of the 
nOPV2 vaccine candidates and, if these were to fall under the scope of GAP III, 
how to interpret or implement the GAP III guidelines in a phase II clinical study. 
The WHO’s Containment Advisory Group concluded that, according to the specific 
terms of usage proposed in the context of the protocol of the CT, the nOPV2 could 
be used outside the containment requirements of GAP III. It also requested the 
13
GMO Regulatory Aspects of Novel Investigational Vaccine Candidates
DOI: http://dx.doi.org/10.5772/intechopen.85341
addition to the trial protocols of environmental monitoring for polioviruses around 
the trial sites, as well as monitoring of close and family contacts of trial subjects 
who continued to shed virus after the end of the trial period [29].
This case exemplifies how different aspects of public health interrelate and 
contribute to the complexity of the regulatory maze to which applicants may be 
confronted when submitting clinical trial applications. Both the consortium and 
Belgian authorities liaised with several regulatory agencies and public health insti-
tutions covering different (international) public health objectives in order to ensure 
that risk management measures were proportional to the risk/safety assessment 
taking into account the intended use, the receiving environment and the likelihood 
of exposure.
4.2 Interplay GMO-pharma
A concern of developers that is acknowledged by the European Commission is 
the lack of harmonization of regulatory procedures of clinical trials with regard to 
the GMO legislative framework. The approval of clinical trials is within the remit 
of the member states and the interplay between the CT regulation and the GMO 
regulation might differ between the member states. This non-harmonized approach 
among member states, detailed under Section 2 of this chapter, is perceived as inef-
fective for the conduct of multinational clinical trials and as an impediment to the 
effective translation of research findings into clinical applications.
Very recently the first steps towards a common procedure for a subset of inno-
vative therapies for human use involving the use of GMOs has been agreed upon 
among member states [30]. It concerns an application form specifically developed 
for clinical trials involving the use of human cells transduced with retroviral or len-
tiviral vector systems. Taking into account that the evaluation of clinical trial with 
respect to the GMO legislation will remain within the remit of national authorities, 
this initiative can be seen as a significant step towards enhanced communication 
among regulators. It is also of high value in light of the upcoming therapeutic 
strategies based on the genetic modification of T cells that target defined antigens 
presented by tumour cells and aids the patient’s own immune system to combat 
malignant diseases, the so-called CAR- and TCR-modified T cells.
The European Commission continues to foster exchanges among member states 
with the aim of developing common application forms, increasing cooperation 
in the risk assessment of applications and identifying issues and questions with 
respect to the scope of the GMO regulatory framework.
4.3 Scientific and technical advice
As already mentioned, at the time of planning a CT with a GMO in a European 
member state, the applicant may be confronted to a complex regulatory proce-
dure, exceeding what is required for a standard study with an IMP. Alongside 
the standard Clinical Trial Application (CTA) and obtaining the advice from the 
ethics committee, questions regarding the GMO status of the IMP and the proper 
mandatory procedural steps may arise. In addition, should the IMP be identified as 
a GMO, the developer will need to identify a distinct competent authority in charge 
of reviewing the application according to the adequate procedural steps.
As outlined earlier, the determination of the GMO procedural pathway for a 
CT in Belgium (meaning whether the CU only or both CU and DR procedures 
must be followed) is subject to a case-by-case examination taking into account 
the possible release of the GMO into the environment and the possible associ-
ated risks. To help the applicant, the competent authority for CTAs offers the 
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possibility to request a scientific and technical advice (STA) prior to the CTA. The 
main objective of the STA is to facilitate the development of vaccines and thera-
peutic products by centralizing and analysing the applicant’s concerns at the time 
of starting the CT.
Within the STA, the applicant is invited to request clarifications on the GMO 
status of the IMP, and on the GMO procedures to be followed, should it decide to 
proceed with the application. The competent authority for CTAs coordinates the 
contacts with experts, centralizes their responses and delivers a formal advice to the 
developer. As such, the STA is a means for developers to engage with the competent 
authorities and advisory bodies early in the process in order to (i) provide informa-
tion that would facilitate further process and (ii) avoid possible misunderstandings 
with regard the GMO status and procedures, which consequently may save time for 
the developer.
5. Discussion and conclusions
With novel technologies poised to result in the development of novel IMPs and 
the overall drive for sustained innovation, a number of regulatory hurdles can be 
identified, which developers face during the development of GMO vaccines. First, 
EU GMO Directives have been transposed into national legislations that include 
different regulatory specificities between member states. Second, new technologies 
may lead to the generation of organisms that are prone to different interpreta-
tions with regard to their (GMO) regulatory status, thereby hampering further 
harmonization of legislations. In addition, aspects such as the relevance of an ERA 
or detection and traceability requirements become in some cases disproportionate 
with respect to the actual risks that novel IMP represent for the general population 
and the environment. Overall, these aspects will increase the need of regulatory 
agencies and advisory bodies to anticipate the deployment of novel IMP, through 
continuous engagement with all stakeholders.
The ECJ ruling has initiated the debate concerning the need to rewrite the GMO 
Directive 2001/18/EC, to have it more fit-for-purpose for the rapid pace of emerg-
ing technologies. This is particularly true for gene-editing technologies. Although it 
is primarily the impact on agri-food applications that has sparked these debates,  
the ECJ ruling will also have an effect on research and development activities and 
the development of a category of IMP. It is anticipated that the current debate on the 
appropriateness of the existing GMO regulatory framework may affect the future 
regulatory status of GMO medicines. This may have consequences through all stages 
of development, from R&D, through clinical translation and marketing authoriza-
tion application.
Aiming to overcome existing hurdles in the regulatory pathway, a number of 
initiatives have been taken in Belgium and among member states. Key challenges are 
being addressed, for example, with the STA at Belgian level, and tangible solutions 
have been formulated, such as the common form for CT with human cells geneti-
cally modified ex vivo by retro- or lentiviral vectors. It is expected that the need for 
harmonization and reviewing regulatory frameworks will be the basis of further 
engagement and exchange between all stakeholders.
New technologies in the field of biotechnology spark promising avenues for the 
development of novel biopharmaceuticals involving GMOs. Enhanced networking 
among all stakeholders should be further promoted in order to subject regula-
tory frameworks to critical review with the aim of keeping them up-to-date with 
upcoming developments and to support innovation while ensuring quality and 
safety for patients, the general population and the environment.
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